Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | PTPRS | Q13332 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 3/20 | 0.42 |
| ▸ | BLM | P54132 | 3/20 | 0.42 |
| ▸ | GABRP | O00591 | 2/20 | 0.42 |
| ▸ | GABRD | O14764 | 2/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.42 |
| ▸ | FBP1 | P09467 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | UGT1A1 | P22309 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977046 | 1.00 | AKT1 (0.48) | AKT1ABCB1ABCG2PTPRSKMT2A | |
| SCHEMBL1975096 | 0.87 | ABCB1 (0.47) | ABCB1ABCG2KDM4EMAPTCYP1A1 | |
| SCHEMBL1974901 | 0.87 | ABCB1 (0.47) | ABCB1ABCG2KDM4EMAPTCYP1A1 | |
| SCHEMBL1977462 | 0.86 | AKT1 (0.63) | AKT1ABCB1ABCG2KMT2AHPGD | |
| SCHEMBL1976105 | 0.86 | AKT1 (0.63) | AKT1ABCB1ABCG2KMT2AHPGD | |
| SCHEMBL1975145 | 0.85 | KMT2A (0.63) | AKT1ABCB1ABCG2PTPRSKMT2A | |
| SCHEMBL1974890 | 0.85 | KMT2A (0.63) | AKT1ABCB1ABCG2PTPRSKMT2A | |
| SCHEMBL1977221 | 0.84 | PTPRS (0.53) | AKT1ABCB1ABCG2PTPRSKMT2A | |
| SCHEMBL1975654 | 0.84 | PTPRS (0.53) | AKT1ABCB1ABCG2PTPRSKMT2A | |
| SCHEMBL1421590 | 0.74 | KDM4E (0.59) | KMT2AKDM4EMEN1MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144194-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | AXOGLIA THERAPEUTICS (LU) | 2011-06-16 | — | — | US | disclosed |
| EP-2112145-A1 | Chromenone derivatives useful for the treatment of neurodegenerative diseases | AxoGlia Therapeutics S.A. (LU) | 2009-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144194-A1 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PARK7, CDR2, SNCA | AKT1 2615/4885ABCB1 2178/4885ABCG2 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.